This month’s newsletter features novel research from our RADR® AI platform and lays a foundation for how AI can be applied to discover new indications for cancer drugs in record times and at significantly reduced costs.
- The research was done in collaboration with the National Cancer Institute (NCI) that was recently published in Frontiers in Drug Discovery.
- The publication highlights how large scale biological data, artificial intelligence, and machine learning were leveraged to rapidly identify Atypical Teratoid Rhabdoid Tumor (ATRT) as an indication for Lantern’s drug candidate LP-184.
- In just over a year, Lantern has advanced its ATRT program for LP-184 from initial in silico RADR® AI insight, to in vitro and in vivo wet lab validation, to discussions with Key Opinion Leaders about a Phase 1 pediatric clinical trial design.
- ATRT is a rare and highly malignant childhood central nervous system cancer with no standard-of-care (SOC) therapy. LP-184’s efficacy for ATRT could fill a void for this cancer with urgent and unmet clinical needs.
- A PDF of the new publication can be downloaded here, or read online on the Frontiers in Drug Discovery website.